Implementation of contemporary radiation therapy planning concepts for pediatric Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group

Hodgson, David C.; Dieckmann, Karin; Terezakis, Stephanie A.; Constine, Louis S.

doi:10.1016/j.prro.2014.05.003

Cited by 38 publications

(31 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some of those ways included 3-dimensional (3D) conformal radiotherapy and intensity-modulated radiotherapy (IMRT). [2][3][4][5] Proton therapy, with its unique characteristics of lower entrance dose, high-dose peak, and precipitous fall-off near the end of beam range, presents another opportunity for more conformal dose distribution and better OAR sparing. 1,6,7 The guidelines represent a set of consensus recommendations by expert radiation oncologists and physicists from different international academic centers.…”

Section: Introductionmentioning

confidence: 99%

Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines

Dabaja

Hoppe

Plastaras

et al. 2018

Blood

View full text Add to dashboard Cite

Among adult lymphoma survivors, radiation treatment techniques that increase the excess radiation dose to organs at risk (OARs) put patients at risk for increased side effects, especially late toxicities. Minimizing radiation to OARs in adults patients with Hodgkin and non-Hodgkin lymphomas involving the mediastinum is the deciding factor for the choice of treatment modality. Proton therapy may help to reduce the radiation dose to the OARs and reduce toxicities, especially the risks for cardiac morbidity and second cancers. Because proton therapy may have some disadvantages, identifying the patients and the circumstances that may benefit the most from proton therapy is important. We present modern guidelines to identify adult lymphoma patients who may derive the greatest benefit from proton therapy, along with an analysis of the advantages and disadvantages of proton treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines

Dabaja

Hoppe

Plastaras

et al. 2018

Blood

View full text Add to dashboard Cite

show abstract

“…The implication of this observation is that even with efforts to limit the surgery-only strategy to those with a single node and TR, occult (microscopic) disease may be present in adjacent nodes or in an adjacent regional chain; such disease is usually eradicated with either chemotherapy or IFRT. This may impact outcomes in studies that either extend the surgical approach to those with more than one identified node at diagnosis or that use involved site radiation therapy, 56 which should be designed to include nodes in adjacent regions.…”

Section: Discussionmentioning

confidence: 99%

Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group

Appel

Chen

Buxton

et al. 2016

JCO

Self Cite

View full text Add to dashboard Cite

show abstract

“…IFRT target volumes for early stage patients typically included adjacent echelons of uninvolved lymph nodes, to account for uncertainty regarding the distribution of disease, variation in patient setup and clinical reluctance to give up the tradition of prophylactic nodal radiation. More recently, guidelines have been developed to fully employ modern image guidance to target nodal areas at risk while limiting the exposure of adjacent normal tissues (Hodgson et al , ). This ‘involved site RT (ISRT)’ takes advantage of the capacity to fuse CT and FDG‐PET imaging from both staging and response assessment to radiotherapy planning CT datasets, thereby allowing more accurate delineation of the nodal areas at risk.…”

Section: Role Of Radiation Therapy In Low‐risk Hlmentioning

confidence: 99%

Current approaches in the management of low risk Hodgkin lymphoma in children and adolescents

Giulino‐Roth

Keller

Hodgson³

et al. 2015

Br J Haematol

Self Cite

View full text Add to dashboard Cite

SummaryThe outcome for children and adolescents with low risk Hodgkin lymphoma (HL) is excellent, with event-free survival >85% and overall survival >95%. Historically, however, treatment has come at the cost of significant long-term toxicity from chemotherapy, radiation or a combination of these. Recent treatment strategies have focused on maintaining high event-free and overall survival while minimizing the use of therapy associated with late effects. The strategies used to achieve this vary greatly among paediatric cooperative groups and there is no one standard treatment for children with low risk HL. This review summaries recent clinical trials in paediatric low risk HL and addresses some of the important considerations when comparing trials, including differences in the definition of low risk HL, differences in outcome among histological subtypes and varying approaches to reduce or eliminate radiation therapy. Recommendations are provided for the treatment of children with low risk HL outside the setting of a clinical trial.

show abstract

Implementation of contemporary radiation therapy planning concepts for pediatric Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group

Cited by 38 publications

References 37 publications

Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines

Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines

Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group

Current approaches in the management of low risk Hodgkin lymphoma in children and adolescents

Contact Info

Product

Resources

About